Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Core Insights - Unicycive Therapeutics is presenting new data on oxylanthanum carbonate (OLC) at the ASN Kidney Week 2025, highlighting significant reductions in pill burden for patients with chronic kidney disease (CKD) [1][2] Group 1: Study Findings - The open-label trial showed a 7-fold reduction in pill volume and a 2-fold reduction in pill count compared to pre-trial phosphate binder therapy [1][2] - The mean daily pill volume decreased from 9.3 cm to 1.4 cm, and the average number of pills taken daily dropped from 8.3 to 3.9 [6] - At the end of the OLC titration period, 91% of patients had serum phosphate levels ≤5.5 mg/dL, up from 59% at screening [6] Group 2: Product Information - OLC is an investigational oral phosphate binder utilizing proprietary nanoparticle technology, aimed at improving patient adherence by reducing the number and size of pills [8] - The company is pursuing FDA approval for OLC through the 505(b)(2) regulatory pathway, supported by data from three clinical studies and a strong patent portfolio [9] Group 3: Industry Context - Hyperphosphatemia is a critical condition affecting nearly all patients with End Stage Renal Disease (ESRD), with over 450,000 individuals in the U.S. requiring medication for phosphate control annually [10] - Effective treatment of hyperphosphatemia is essential to reduce associated risks of increased mortality and hospitalization in CKD patients on dialysis [10]